High ABCG4 Expression Is Associated with Poor Prognosis in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Aug 14

PMID 26270652

Citations 7

Authors

Guang Yang

Xue-Jiao Wang

Li-Jun Huang

Yong-An Zhou

Feng Tian

Jin-Bo Zhao

Peng Chen

Bo-Ya Liu

Miao-Miao Wen

Xiao-Fei Li

Zhi-Pei Zhang

Affiliations

Soon will be listed here.

Abstract

ATP-binding cassette (ABC) transporters are associated with poor response to chemotherapy, and confer a poor prognosis in various malignancies. However, the association between the expression of the ABC sub-family G member 4 (ABCG4) and prognosis in patients with non-small-cell lung cancer (NSCLC) remains unclear. NSCLC tissue samples (n = 140) and normal lung tissue samples (n = 90) were resected from patients with stage II to IV NSCLC between May 2004 and May 2009. ABCG4 mRNA and protein expressions were detected by RT-PCR, western blot, and immunohistochemistry. Patients received four cycles of cisplatin-based post-surgery chemotherapy and were followed up until May 31st, 2014. ABCG4 positivity rate was higher in NSCLC than in normal lung tissues (48.6% vs. 0%, P<0.001) and ABCG4 expression was significantly associated with poor differentiation, higher tumor node metastasis (TNM) stage, and adenocarcinoma histological type (all P<0.001). Univariate (HR = 2.284, 95%CI: 1.570-3.324, P<0.001) and multivariate (HR = 2.236, 95%CI: 1.505-3.321, P<0.001) analyses showed that ABCG4 expression was an independent factor associated with a poor prognosis in NSCLC. Patients with ABCG4-positive NSCLC had shorter median survival than ABCG4-negative NSCLC (20.1 vs. 43.2 months, P<0.001). The prognostic significance of ABCG4 expression was apparent in stages III and IV NSCLC. In conclusion, high ABCG4 expression was associated with a poor prognosis in patients with NSCLC treated with cisplatin-based chemotherapy.

Citing Articles

Long non-coding RNA DSCAS regulates cisplatin sensitivity in lung squamous cell carcinoma by competitively binding to miR-646-3p.

Liu H, Lu C, Li P, Jia H, Wang Y, Cheng J Heliyon. 2023; 9(6):e16865.

PMID: 37360104 PMC: 10285167. DOI: 10.1016/j.heliyon.2023.e16865.

Investigation of the effects of overexpression of jumping translocation breakpoint (JTB) protein in MCF7 cells for potential use as a biomarker in breast cancer.

Jayathirtha M, Neagu A, Whitham D, Alwine S, Darie C Am J Cancer Res. 2022; 12(4):1784-1823.

PMID: 35530281 PMC: 9077082.

Bixin and fucoxanthin sensitize human lung cancer and cervical cancer cell to cisplatin in vitro.

Nurcahyanti A, Kusmita L, Wink M BMC Res Notes. 2021; 14(1):454.

PMID: 34922615 PMC: 8684137. DOI: 10.1186/s13104-021-05866-4.

Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy.

Kryczka J, Kryczka J, Czarnecka-Chrebelska K, Brzezianska-Lasota E Int J Mol Sci. 2021; 22(16).

PMID: 34445588 PMC: 8396273. DOI: 10.3390/ijms22168885.

Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment.

Fernandez L, Gomez de Cedron M, Ramirez de Molina A Front Oncol. 2020; 10:577420.

PMID: 33194695 PMC: 7655926. DOI: 10.3389/fonc.2020.577420.

References

Li J, Li Z, Du Y, Li X, Bao Q, Chen P . Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer. 2009; 10(6):414-21. DOI: 10.3816/CLC.2009.n.078. View

van Meer G, Halter D, Sprong H, Somerharju P, Egmond M . ABC lipid transporters: extruders, flippases, or flopless activators?. FEBS Lett. 2005; 580(4):1171-7. DOI: 10.1016/j.febslet.2005.12.019. View

Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B . The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today. 2008; 13(9-10):379-93. DOI: 10.1016/j.drudis.2007.12.010. View

Pohl A, Devaux P, Herrmann A . Function of prokaryotic and eukaryotic ABC proteins in lipid transport. Biochim Biophys Acta. 2005; 1733(1):29-52. DOI: 10.1016/j.bbalip.2004.12.007. View

Fujiyoshi M, Ohtsuki S, Hori S, Tachikawa M, Terasaki T . 24S-hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical- and apoE isoform-dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression. J Neurochem. 2006; 100(4):968-78. DOI: 10.1111/j.1471-4159.2006.04240.x. View

Prochazka L, Koudelka S, Dong L, Stursa J, Goodwin J, Neca J . Mitochondrial targeting overcomes ABCA1-dependent resistance of lung carcinoma to α-tocopheryl succinate. Apoptosis. 2013; 18(3):286-99. DOI: 10.1007/s10495-012-0795-1. View

Murphy A, Bijl N, Yvan-Charvet L, Welch C, Bhagwat N, Reheman A . Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med. 2013; 19(5):586-94. PMC: 3683965. DOI: 10.1038/nm.3150. View

Tamaki A, Ierano C, Szakacs G, Robey R, Bates S . The controversial role of ABC transporters in clinical oncology. Essays Biochem. 2011; 50(1):209-32. PMC: 6944313. DOI: 10.1042/bse0500209. View

Reungwetwattana T, Weroha S, Molina J . Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2011; 13(4):252-66. DOI: 10.1016/j.cllc.2011.09.004. View

10.

Wang N, Lan D, Chen W, Matsuura F, Tall A . ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A. 2004; 101(26):9774-9. PMC: 470750. DOI: 10.1073/pnas.0403506101. View

11.

Ross D, Yang W, Abruzzo L, Dalton W, Schneider E, Lage H . Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst. 1999; 91(5):429-33. DOI: 10.1093/jnci/91.5.429. View

12.

Hollenstein K, Dawson R, Locher K . Structure and mechanism of ABC transporter proteins. Curr Opin Struct Biol. 2007; 17(4):412-8. DOI: 10.1016/j.sbi.2007.07.003. View

13.

Arriagada R, Auperin A, Burdett S, Higgins J, Johnson D, Le Chevalier T . Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010; 375(9722):1267-77. PMC: 2853682. DOI: 10.1016/S0140-6736(10)60059-1. View

14.

. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014; 383(9928):1561-71. PMC: 4022989. DOI: 10.1016/S0140-6736(13)62159-5. View

15.

Falasca M, Linton K . Investigational ABC transporter inhibitors. Expert Opin Investig Drugs. 2012; 21(5):657-66. DOI: 10.1517/13543784.2012.679339. View

16.

Silverton L, Dean M, Moitra K . Variation and evolution of the ABC transporter genes ABCB1, ABCC1, ABCG2, ABCG5 and ABCG8: implication for pharmacogenetics and disease. Drug Metabol Drug Interact. 2011; 26(4):169-79. PMC: 7372709. DOI: 10.1515/DMDI.2011.027. View

17.

Annilo T, Tammur J, Hutchinson A, Rzhetsky A, Dean M, Allikmets R . Human and mouse orthologs of a new ATP-binding cassette gene, ABCG4. Cytogenet Cell Genet. 2002; 94(3-4):196-201. DOI: 10.1159/000048816. View

18.

Graf G, Yu L, Li W, Gerard R, Tuma P, Cohen J . ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem. 2003; 278(48):48275-82. DOI: 10.1074/jbc.M310223200. View

19.

Ota S, Ishii G, Goto K, Kubota K, Kim Y, Kojika M . Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer. 2008; 64(1):98-104. DOI: 10.1016/j.lungcan.2008.07.014. View

20.

Langheim S, Yu L, von Bergmann K, Lutjohann D, Xu F, Hobbs H . ABCG5 and ABCG8 require MDR2 for secretion of cholesterol into bile. J Lipid Res. 2005; 46(8):1732-8. DOI: 10.1194/jlr.M500115-JLR200. View